Free Trial

This company has been marked as potentially delisted and may not be actively trading.

RXi Pharmaceuticals (RXII) Competitors

RXi Pharmaceuticals logo

RXII vs. LNAI, TAOX, NNVC, EGRX, IBIO, AEON, NRBO, OBSV, CPHI, and GRAY

Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Lunai Bioworks (LNAI), Synaptogenix (TAOX), NanoViricides (NNVC), Eagle Pharmaceuticals (EGRX), Ibio (IBIO), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), ObsEva (OBSV), China Pharma (CPHI), and Graybug Vision (GRAY).

RXi Pharmaceuticals vs. Its Competitors

Lunai Bioworks (NASDAQ:LNAI) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Lunai Bioworks' average media sentiment score of 0.00 equaled RXi Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Lunai Bioworks Neutral
RXi Pharmaceuticals Neutral

Lunai Bioworks has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RXi Pharmaceuticals has higher revenue and earnings than Lunai Bioworks. RXi Pharmaceuticals is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lunai BioworksN/AN/A-$178.01M-$7.70-0.16
RXi Pharmaceuticals$10K924.18-$12.45M-$4.20-0.50

Lunai Bioworks has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. Lunai Bioworks' return on equity of -222.12% beat RXi Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lunai BioworksN/A -222.12% -152.88%
RXi Pharmaceuticals -4,990.20%-412.15%-179.54%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lunai Bioworks
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
RXi Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Lunai Bioworks beats RXi Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get RXi Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXII vs. The Competition

MetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$9.24M$1.08B$6.19B$10.57B
Dividend YieldN/A4.84%5.72%4.81%
P/E Ratio-0.501.3085.5427.12
Price / Sales924.1829.96610.04131.73
Price / CashN/A17.6337.1060.81
Price / Book2.748.0712.236.52
Net Income-$12.45M-$7.36M$3.33B$276.93M

RXi Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXII
RXi Pharmaceuticals
N/A$2.11
-0.5%
N/A-34.8%$9.24M$10K-0.50N/A
LNAI
Lunai Bioworks
N/A$1.26
+3.3%
N/AN/A$29.21MN/A-0.1620News Coverage
TAOX
Synaptogenix
0.0617 of 5 stars
$8.26
-14.0%
N/AN/A$28.80M$3.96K-0.414News Coverage
Gap Up
NNVC
NanoViricides
0.8158 of 5 stars
$1.33
-1.5%
N/A+0.7%$23.18MN/A-1.8520News Coverage
Short Interest ↓
EGRX
Eagle Pharmaceuticals
2.0677 of 5 stars
$1.50
flat
N/A+130.8%$19.48M$257.55M0.00100
IBIO
Ibio
1.0317 of 5 stars
$0.82
+2.5%
N/AN/A$16.61M$400K-0.47100Analyst Upgrade
Short Interest ↓
AEON
AEON Biopharma
0.5331 of 5 stars
$1.14
-3.0%
N/A-98.6%$13.17MN/A6.285Gap Down
NRBO
NeuroBo Pharmaceuticals
N/A$0.99
+1.3%
N/A-67.1%$8.54MN/A0.0010Gap Up
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/A0.0050
CPHI
China Pharma
0.153 of 5 stars
$1.90
+1.1%
N/A-92.3%$6.18M$4.40M0.00250Short Interest ↑
GRAY
Graybug Vision
N/A$3.26
+3.0%
N/A-21.5%$5.12MN/A-1.8827High Trading Volume

Related Companies and Tools


This page (NASDAQ:RXII) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners